# Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine

Study · id `cardio:ct-nct01373619` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01373619](<https://clinicaltrials.gov/study/NCT01373619>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01373619

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

## Technical summary

Registry record NCT01373619. Non-randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2011-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 150 participants (enrolled count; ClinicalTrials.gov record NCT01373619, source copy `cardio:ctgov-nct01373619-2012-01-19`, retrieved 2026-10-26)
- Start date: 2010-01 (registry gives no type) (ClinicalTrials.gov record NCT01373619, source copy `cardio:ctgov-nct01373619-2012-01-19`, retrieved 2026-10-26)
- Primary completion: 2011-01 (actual) (ClinicalTrials.gov record NCT01373619, source copy `cardio:ctgov-nct01373619-2012-01-19`, retrieved 2026-10-26)
- Completion: 2012-01 (actual) (ClinicalTrials.gov record NCT01373619, source copy `cardio:ctgov-nct01373619-2012-01-19`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT01373619, source copy `cardio:ctgov-nct01373619-2012-01-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01373619-2012-01-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine
- Condition: Heart Failure
- Intervention (Drug): Ivabradine
- Lead sponsor: University of Campania Luigi Vanvitelli
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: University of Campania Luigi Vanvitelli (`cardio:org-university-of-campania-luigi-vanvitelli`)

## Provenance

Content hash: e01576a0132eec61a3f140f15040f0647185c88c17a6298707655ed79022322a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
